[Federal Register: November 16, 2007 (Volume 72, Number 221)]
[Notices]               
[Page 64676-64677]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr16no07-137]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated July 31, 2007, and published in the Federal 
Register on August 9, 2007, (72 FR 44860), Cambrex North Brunswick, 
Inc., Technology Centre of New Jersey, 661 Highway One, North 
Brunswick, New Jersey 08902, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk

[[Page 64677]]

manufacturer of the basic classes of controlled substances listed in 
schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
N-Ethylamphetamine (1475)...................  I
Tetrahydrocannabinols (7370)................  I
2,5-Dimethoxyamphetamine (7396).............  I
3,4-Methylenedioxyamphetamine (7400)........  I
4-Methoxyamphetamine (7411).................  I
Amphetamine (1100)..........................  II
Methamphetamine (1105)......................  II
Methylphenidate (1724)......................  II
Pentobarbital (2270)........................  II
Phenylacetone (8501)........................  II
Hydromorphone (9150)........................  II
Hydrocodone (9193)..........................  II
Methadone (9250)............................  II
Methadone intermediate (9254)...............  II
Morphine (9300).............................  II
Sufentanil (9740)...........................  II
Fentanyl (9801).............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Cambrex North Brunswick, Inc. to manufacture the listed basic classes 
of controlled substances is consistent with the public interest at this 
time. DEA has investigated Cambrex North Brunswick, Inc. to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

    Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-22468 Filed 11-15-07; 8:45 am]

BILLING CODE 4410-09-P